Literature DB >> 28123922

Serum Apo A-1 and Its Role as a Biomarker of Coronary Artery Disease.

Salma Rahim1, Hafez Mohammad A Abdullah2, Yousaf Ali3, Uzma I Khan2, Waqas Ullah4, Muhammad A Shahzad5, Muhammad Waleed2.   

Abstract

OBJECTIVES: To evaluate the role of apolipoprotein(Apo A-1) as a biomarker of coronary artery disease (CAD) and its comparison with the traditional marker high-density lipoprotein (HDL).
METHODOLOGY: One hundred patients proven to have coronary artery disease by angiography were recruited and their serum biomarkers were compared with 100 normal individuals adjusted for age and sex. RESULT: The mean +/-standard deviation (SD) value of plasma Apo A-1 levels in the normal individuals were observed to be 207.42 +/- 41.35 (mg/dL) against 90.69 +/- 20.77 (mg/dL) in the cardiac patients. On the other hand the serum HDL levels were 52.93 +/-33.58 (mg/dL) in the normal individuals and 37.86 +/- 23.19 (mg/dL) in the cardiac patients. Both of these differences were statistically significant (p < 0.001). For Apo A-1, a large proportion of patients (85%) were found to be in the abnormal range when compared to the control group in which only 7% had an abnormal value. For HDL, a majority (70%) of the cardiac patients had abnormal values while 40% of the normal individuals also had abnormal values. The sensitivity of Apo A-1 for detecting CAD was 85%, while for HDL, it was only 69%. Similarly, the specificity of Apo A-1 for detecting CAD was 93%, while for HDL, it was 60%. When plotted on a receiver operating characteristic (ROC) curve, Apo A-1 had a much larger area under the curve when compared to HDL.
CONCLUSION: This study suggests that Apo A-1 may, in fact, be more sensitive than HDL as a predictor of CAD. However, to completely elucidate its role as a biomarker, to set target serum levels and to increase its clinical use, further studies are required.

Entities:  

Keywords:  apo a-1; coronary artery disease; hdl

Year:  2016        PMID: 28123922      PMCID: PMC5262432          DOI: 10.7759/cureus.941

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  27 in total

Review 1.  The rationale for using apoA-I as a clinical marker of cardiovascular risk.

Authors:  P J Barter; K-A Rye
Journal:  J Intern Med       Date:  2006-05       Impact factor: 8.989

2.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors:  G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

Review 3.  High-density lipoprotein--the clinical implications of recent studies.

Authors:  D J Gordon; B M Rifkind
Journal:  N Engl J Med       Date:  1989-11-09       Impact factor: 91.245

4.  Plasma apoproteins and the severity of coronary artery disease.

Authors:  S P Sedlis; K B Schechtman; P A Ludbrook; B E Sobel; G Schonfeld
Journal:  Circulation       Date:  1986-05       Impact factor: 29.690

5.  Amyloid contained in the knee joint meniscus is formed from apolipoprotein A-I.

Authors:  Alan Solomon; Charles L Murphy; Daniel Kestler; Daniel Coriu; Deborah T Weiss; Josef Makovitzky; Per Westermark
Journal:  Arthritis Rheum       Date:  2006-11

6.  Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Authors:  S Matthijs Boekholdt; Benoit J Arsenault; G Kees Hovingh; Samia Mora; Terje R Pedersen; John C Larosa; K M A Welch; Pierre Amarenco; David A Demicco; Andrew M Tonkin; David R Sullivan; Adrienne Kirby; Helen M Colhoun; Graham A Hitman; D John Betteridge; Paul N Durrington; Michael B Clearfield; John R Downs; Antonio M Gotto; Paul M Ridker; John J P Kastelein
Journal:  Circulation       Date:  2013-08-21       Impact factor: 29.690

7.  Apolipoproteins A-I and B-markers in coronary risk evaluation.

Authors:  Lucica Agoston-Coldea; D Zdrenghea; Dana Pop; Alexandra Crăciun; M L Rusu; Teodora Mocan
Journal:  Rom J Intern Med       Date:  2007

8.  Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study.

Authors:  Gérald Luc; Jean-Marie Bard; Dominique Arveiler; Jean Ferrieres; Alun Evans; Philippe Amouyel; Jean-Charles Fruchart; Pierre Ducimetiere
Journal:  Atherosclerosis       Date:  2002-08       Impact factor: 5.162

9.  Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure.

Authors:  Masahiko Iwaoka; Jyun-ei Obata; Makoto Abe; Takamitsu Nakamura; Yoshinobu Kitta; Yasushi Kodama; Ken-ichi Kawabata; Hajime Takano; Daisuke Fujioka; Yukio Saito; Tsuyoshi Kobayashi; Hideyuki Hasebe; Kiyotaka Kugiyama
Journal:  J Card Fail       Date:  2007-05       Impact factor: 5.712

10.  ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients.

Authors:  A H Liem; A P van de Woestijne; H W O Roeters van Lennep; A H Zwinderman; W A van der Steeg; J W Jukema
Journal:  Curr Med Res Opin       Date:  2008-02       Impact factor: 2.580

View more
  5 in total

Review 1.  Genetic control of apoprotein A-I and atheroprotection: some insights from inbred strains of mice.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

2.  Metal additive manufacturing and possible clinical markers for the monitoring of exposure-related health effects.

Authors:  Stefan A Ljunggren; Liam J Ward; Pål Graff; Anders Persson; Malin Leijon Lind; Helen Karlsson
Journal:  PLoS One       Date:  2021-03-18       Impact factor: 3.240

3.  Predictive value of the apolipoprotein B/A1 ratio in intracerebral hemorrhage outcomes.

Authors:  Rasha Alsamani; Zhang Limin; Wu Jianwei; Wang Dan; Sun Yuehong; Liu Ziwei; Xu Huiwen; Wang Dongzhi; Shi Yijun; Qian Lingye; Zhao Xingquan; Zhang Guojun
Journal:  J Clin Lab Anal       Date:  2022-06-12       Impact factor: 3.124

4.  Estimation of apolipoprotein A in early onset ST-segment elevation myocardial infarction.

Authors:  Ameen Mosa Mohammad; Ahmed Hasan Yousif; Bayar Ahmed Qasim; Joma Aziz Joma; Saad Younis Saeed
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-11-13

5.  Structural analysis of lecithin:cholesterol acyltransferase bound to high density lipoprotein particles.

Authors:  Kelly A Manthei; Dhabaleswar Patra; Christopher J Wilson; Maria V Fawaz; Lolita Piersimoni; Jenny Capua Shenkar; Wenmin Yuan; Philip C Andrews; John R Engen; Anna Schwendeman; Melanie D Ohi; John J G Tesmer
Journal:  Commun Biol       Date:  2020-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.